Kornimate/medical-research-clean huggingface dataset:
azithromycin in combination with chloroquine versus chloroquine in the eradication of asymptomatic plasmodium falciparum

Conditions: Malaria, Falciparum

Summary: the purpose of this study is to determine if azithromycin in combination with chloroquine is superior to chloroquine alone in eradicating p. falciparum asexual parasitemia in asymptomatic, semi-immune adults in western kenya.

the trial was terminated prematurely 9 november 2004 due to the inability to recruit the planned number of subjects. there were no safety or efficacy concerns regarding the study in the decision to terminate the trial.

Eligibility criteria:
inclusion criteria: * healthy adult: male or female * asymptomatic mono-infection with p. falciparum parasitemia with a parasite density of 1000 - 30,000 parasites/î¼l * age 18 years to 60 years * willingness to sign and ability to understand consent form * willingness and ability to return for scheduled follow up visits exclusion criteria: * mixed malaria infection by giemsa smear * history of allergy to or hypersensitivity to chloroquine, azithromycin or other macrolides (e.g. erythromycin, clarithromycin) * any of the following: a.) antimalarial therapy administered in the past 4 weeks, including quinine therapy or an artemisinin derivative; or b.) an antibacterial with known antimalarial activity (including, erythromycin, doxycycline, clindamycin, cotrimoxazole) within one week prior to enrollment into the study * fever, history of fever in past 48 hours, or signs/symptoms of malaria (including acute or subacute headache, nausea, or vomiting) * inability to swallow oral medication * laboratory evidence or history of significant cardiovascular, liver, hematologic or renal functional abnormality * any situation which could prevent the patient from returning to follow up visits * pregnancy or breast feeding * any other concurrent illness that may confound the result * any other condition or circumstance that in the opinion of the investigator may pose a threat to the study participant or study
effect of conjugated linoleic acid alone and in conjunction with vitamin e in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: conjugated linoleic acids (clas) comprise a family of linoleic acid (18:2n-6; la) isomers that are formed by biohydrogenation and oxidation processes in nature. the main form of cla, cis-9, trans-11-18:2, can be produced directly by bacterial hydrogenation in the rumen or by delta-9 desaturation of the co-product vaccenic acid (trans-11-18:1) in most mammalian tissues including man. the second most abundant isomer of cla is the trans-10, cis-12-18:2 form. observations clearly emphasize that differences exist between mammalian species in their response to clas with mice being the most sensitive. the majority of studies on body compositional effects (i.e. fat loss, lean gain), on cancer and cardiovascular disease attenuation, on insulin sensitivity and diabetes and on immune function have been conducted with a variety of animal models. recent studies indicate that some but not all of the effects observed in animals also pertain to human volunteers. reports of detrimental effects of cla intake appear to be largely in mice and due mainly to the trans-10, cis-12 isomer. suggestions of possible deleterious effects in man due to an increase in oxidative lipid products (isoprostanes) with trans-10, cis-12 cla ingestion require substantiation. unresponsiveness to antioxidants of these non-enzymatic oxidation products casts some doubt on their physiological relevance. we hypothesized that supplementation with cla + an antioxidant (vitamin e) in patients with diabetes mellitus may have beneficial effects on glycemic control and insulin sensitivity.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus \> 5 years * hba1c ≤ 9% * overweight or obese (bmi ≥ 25 kg/m2 and ≤ 30 kg/m2) * age ≥ 30 and ≤ 70 years (postmenopausal if female) * stable medical therapy for past 3 months * stable serum glucose for past 3 months (128-180 mg/dl) * age between 30 to 50 * use of metformin * tg \< 240 mg/dl * no alcohol, no insulin, no smoke * no pregnancy, no menopause exclusion criteria: * personal history of coronary heart disease * cerebrovascular disease or vascular disease * renal or hepatic disease * inflammatory diseases and thyroid diseases within the last years * use of drugs known to affect glycemic control, beta blockers, any change in daily activity profile, and diet

Keywords: diabetes mellitus cla antioxidant glycemic control
finger pulse oximeters in hosptial setting

Conditions: Hypoxia; Respiratory Failure With Hypoxia

Summary: pulse oximetry is a well-established, non-invasive measurement tool used to estimate arterial oxygen saturation. the accuracy of these cheap, readily available finger pulse oximeters has not been robustly assessed in a clinical trial however. it is vital for clinical practice that this technology is reliable in tracking changes in oxygen saturations at times of ill health as varying physiological parameters may, in theory, contribute to inaccurate readings. this study will investigate whether these new devices provide a sufficiently accurate measurement of oxygen levels in the blood (when compared to arterial blood gas sampling) to endorse their use in routine hospital practice.

the investigators propose to assess the margins of agreement between newer commercially available finger pulse oximeters and arterial blood gases in a hospital setting. eligible participants requiring blood gas assessment will be identified by members of the clinical team, who will inform the research team investigator. arterial blood gas sampling is usually performed in patients who are breathless with low oxygen levels. at the time of arterial blood gas sampling, the three finger pulse oximeters will be placed on each of three fingers of the participant. the pulse oximeters are small cubic devices, each about the size of a matchbox that sits lightly over the fingernail. light is emitted from the device and passes through the nailbed.the blood oxygen levels can then be estimated by measuring the absorption of different wavelengths of light. the participant will be asked to remain seated and still for 2mins until steady state is achieved. at this time readings will be taken from each machine. the contemporaneous measurements of oxygen saturation using gold standard, invasive arterial blood gas sampling and new non-invasive portable pulse oximeters will allow the investigators to evaluate the accuracy of these devices and evaluate their clinical usefulness in the hospital setting.

Eligibility criteria:
inclusion criteria: * hospital inpatients deemed by the clinical team to require arterial blood gas sampling (typically this would represent patients who are complaining of breathlessness or who have low oxygen saturations) * informed consent exclusion criteria: * inability to consent (including language barrier) * age \<16 years old
prepping for the talk: helping trusted adults and youth talk about sexual health

Conditions: HIV Prevention; Sexual Health

Summary: the goal of this study is to help young people talk to trusted adults (including their parents, but also other adults) about sexual health more openly and honestly- including how to prevent sexually transmitted diseases like hiv - while also respecting a young person's right to privacy. if youth don't have a parent they can talk to about sexual health, we want to help them find a trusted adult to talk to. we also want to help youth take control of their own health by learning about different ways to protect their health.


Eligibility criteria:
inclusion criteria: * age 14-17 * assigned male * oral or anal sex with an assigned male * live in the united states * english-speaking exclusion criteria: * none
sputum clearance effects of hypertonic saline in non-cystic fibrosis bronchiectasis

Conditions: Bronchiectasis

Summary: this study aims to analyze whether the hypertonic saline nebulization enhances sputum clearance effects, reduces the impact on cough severity and their level of safety and tolerability in a population with non-cystic fibrosis bronchiectasis (ncfbe). in addition, this trial aims to compare these health outcomes among 3 nebulized solutions: hypertonic saline (7%); hyaluronic acid + hypertonic saline (7%); isotonic saline (0,9%).

the present study will be a randomized, double-blind, crossover trial. each nebulized solution \[hypertonic saline (7%); hyaluronic acid + hypertonic saline (7%); isotonic saline (0,9%)\] will be administrated during 4 days. after each inhalation, all patients will carry out a bronchial drainage session (autogenic drainage technique). all patients recruited will perform the three arms of intervention. in this way, each patient will be able to act as his/her own control. a 7 days washout period will be required among the different solutions to avoid carryover effects. during the study period the patients' pharmacological treatment remained unchanged.

Eligibility criteria:
inclusion criteria: 1. non-cystic fibrosis bronchiectasis (ncfbe) diagnosed by high resolution computed tomographic 2. mean sputum production ≥ 10 ml /24h. 3. clinical stability in the last 4 weeks 4. to be able to understand how to perform inhalation and the physiotherapy session. 5. to be able to provide written, informed consent exclusion criteria: 1. forced expiratory volume in 1 second \< 30% pred. ; total lung capacity \< 45% pred. 2. performing nebulization with any hyperosmolar agents, previously 3. allergic bronchopulmonary aspergillosis diagnosis 4. not to be able to overcome the safety test pre-intervention (oxygen saturation levels drop to \< 90% and/or forced expiratory volume in 1 second decline more than \< 12% from baseline during the nebulization process)

Keywords: sputum clearance cough severity hypertonic saline acid hyaluronic tolerability
community-based physical activity intervention for underserved cancer survivors

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial evaluates a community-based physical activity program for underserved cancer survivors. cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning. historically, community sites (local and national) have not been staffed to offer support services such as physical, and occupational therapies (everyday life activities to promote health and well-being) or nutrition counselling, and do not offer a whole-person model of care. in this study, researchers have partnered with the ymca to provide tailored home-based exercise programs for underserved cancer patients and survivors. accessing exercise professionals may allow patients to prevent acute problems from becoming chronic, long-lasting physically weak impairments that directly influence patients' quality of life.

primary objective: i. to assess the feasibility and acceptability of a community-based 12-week physical activity intervention. secondary objective: i. to assess the effectiveness of a virtual physical activity intervention by evaluating pre-post changes in quality of life (qol). exploratory objective (optional): i. to virtually assess changes in functional performance in a small subgroup. outline: participants participate in virtual exercise classes at least three times a week (tiw) over 20-60 minutes for 12 weeks. participants are expected to work towards achieving the national physical activity exercise guidelines of 150 minutes of moderate intensity aerobic based physical activity and 2-3 strength training sessions each week. after completion of study intervention, patients are followed up at 1 week.

Eligibility criteria:
inclusion criteria: * have had a previous cancer diagnosis or are a caregiver for a patient who has had a previous cancer diagnosis * not in active treatment for cancer * over 18 years of age exclusion criteria: * have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, atrial fibrillation (afib), multiple myeloma, or psychiatric illness/social situations that would limit compliance with study requirements * have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise * are pregnant or nursing * are unwilling or unable to follow protocol requirements * have any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study
a prospective study of apatinib plus concurrent neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to assess the efficacy and safety of apatinib plus concurrent neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: 1. age:18 to 70 years old (man or female); 2. pathologically diagnosed with esophageal squamous cell carcinoma; 3. patients with stage for ⅱ-ⅲ(t2-4n0/+m0) (according to transesophageal ultrasonography; 4. patients with measurable lesions(according to the criteria in recist1.1); 5. eastern cooperative oncology group (ecog) performance status of 0-2; 6. life expectancy greater than or equal to 3 months; 7. major organ function has to meet the following certeria: (1) for results of blood routine test 1. hb≥80g/l; 2. anc≥1.5×109/l; 3. plt≥90×109/l; (2) for results of blood biochemical test a) alt and ast≤2.5×uln; b) tbil\<1.5×uln; c) serum creatinine ≤1.5×uln; 8. doctors believe that treatment can bring benefits to patients; 9. participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up. exclusion criteria: 1. have received prior treatment with chemotherapy or radiotherapy； 2. have high blood pressure and antihypertensive drug treatment can not control; 3. patients with severe cardiovascular disease ; 4. accompanied by esophageal perforation and esophagotracheal fistula; 5. patients with active bleeding or bleeding tendency; 6. pregnant or lactating women; 7. the researchers think inappropriate.
evaluation of chitosan scaffold and mineral trioxide aggregate pulpotomy in mature permanent molars with irreversible pulpitis

Conditions: Pulpitis - Irreversible

Summary: the aim of this study is to evaluate the clinical and radiographic outcomes of chitosan scaffold and mineral trioxide aggregate (mta) when used as pulpotomy agents in mature permanent teeth with irreversible pulpitis.

thirty permanent mandibular molars of patients with signs and symptoms of irreversible pulpitis will be selected. they will be randomly allocated into two groups, group 1(chitosan scaffold/ mta pulp dressing materials), group 2 (mta pulp dressing material). a single visit full pulpotomy procedure will be carried out. chitosan scaffold and / or mta will be used as the pulp dressing materials. the teeth will be then restored with base of glass ionomer cement followed by composite restoration.

Eligibility criteria:
inclusion criteria: * participants free from any systemic disease. * deep caries in a permanent lower molar with mature roots. * probing pocket depth and mobility within normal limits. * no signs of pulpal necrosis including sinus tract or swelling. * vital bleeding pulp tissue should be present in all canals after complete pulpotomy. * the tooth is restorable. * clinical diagnosis of symptomatic irreversible pulpitis based on subjective and objective examinations: * subjective examination: patients complaining of intermittent or spontaneous pain or pain exacerbated by dramatic temperature changes especially to cold stimuli and lasting for a few seconds to several hours. * objective examination: * clinical examination: teeth that will experience immediate, excruciatingly painful sensation as soon as the cold stimulus is placed on and which may last for a while even after the removal of the stimulus. * radiographic examination: preoperative radiographs will be taken using a paralleling device. * the periapical index developed by orstavik et al. (1986)(35) will be used to score cases with periapical rarefaction during diagnosis and follow-up periods. it consists of five categories: 1. normal periapical structures. 2. small changes in bone structures. 3. change in bone structure with mineral loss. 4. periodontitis with well-defined radiolucent area. 5. severe periodontitis with exacerbating features. score 1 and 2 are considered healthy, score 3-5 are considered diseased * the teeth that will be included should have score 1 or 2. exclusion criteria: * negative response to cold testing. * no pulp exposure after caries excavation. * bleeding could not be controlled in 10 minutes after 2.5% naocl * absence of bleeding from any of the canals. * teeth with radiographic signs of internal resorption. * pulpal calcifications. * participants with stainless-steel wires and brackets.
characterization and verification of the intensive care standard operating procedure (sop) adherence of the treated covid-19 patients

Conditions: Covid19

Summary: as part of the internal quality management (qm project), this retrospective cohort study examines the adherence to standard operating procedures (sop) of the covid-19 patients treated since january 1st, 2020 to february 28th, 2021 in intensive care units of the clinic for anesthesiology m.s. operative intensive care medicine ccm / cvk.


Eligibility criteria:
inclusion criteria: * during the intensive care stay with sars-cov-2 infected intensive care patients of the charité - universitätsmedizin berlin, admitted to the intensive care units of the department of anesthesiology and operative intensive care medicine (ccm / cvk) * treatment period: 01/01/2020 to 02/28/2021 * at least 18 years old exclusion criteria: • incomplete electronic documentation
plan for systematic identification of lung cancers of occupational origin: implementation study

Conditions: Broncho Pulmonary Cancer

Summary: the main objective is to identify obstacles and elements facilitating the implementation of a tracking device broncho pulmonary cancer during the course of care. the secondary objective is to assess patient knowledge and information received on their previous occupational exposure during their professional activity. this is a prospective multicenter study of qualitative methodology through in-depth interviews conducted with patients treated at icln and chu saint-etienne


Eligibility criteria:
inclusion criteria: * primitive cbp patients; * patients employees or have been employees of the general scheme and / or the agricultural social security system; * patients understand french. exclusion criteria: * patients recognized occupational disease for cbp; * recognized disability in patients for cbp by the social security system; * patients who have never been employees of the general or the agricultural social security system plan * patients already included in phase 1 of the study; * refusal of participation, signed consent major patients protected under guardianship; * patients unable to understand the course of the study.
a study of safety and efficacy of vaniprevir administered with pegylated-interferon and ribavirin in japanese participants with chronic hepatitis c infection (7009-016)

Conditions: Hepatitis C

Summary: the study evaluates safety and efficacy of vaniprevir (mk7009), when administered with pegylated-interferon (peg-ifn) and ribavirin, in japanese patients with hepatitis c infection. the primary hypotheses are that 1.) the proportion of patients achieving rapid viral response (rvr) in one or more of the vaniprevir treatment groups is superior to that in the placebo group, when each is administered concomitantly with pegylated interferon (peg-ifn) α-2a and ribavirin; and 2.) vaniprevir at the studied doses is well tolerated compared with placebo, when each is administered concomitantly with peg-ifn α-2a and ribavirin for 28 days.


Eligibility criteria:
inclusion criteria: * has chronic genotype 1 hepatitis c infection exclusion criteria: * has not tolerated previous course of peg-ifn and ribavirin * has hiv * has hepatitis b * has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-ifn and ribavirin
weekly gemcitabine and trastuzumab in the treatment of patients with human epidermal growth factor receptor 2 (her2) positive metastatic breast cancer

Conditions: Breast Cancer

Summary: due to its remarkable activity as salvage treatment in women with metastatic breast cancer as well as the additive activity observed for gemcitabine administered in combination with trastuzumab, the clinical activity of the combination of gemcitabine administered with trastuzumab represents an exciting and ideal combination to further evaluate in her 2 over-expressing metastatic breast cancer patients.

upon determination of eligibility, all patients will be receive: gemcitabine + trastuzumab

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * her-2 positive metastatic breast cancer confirmed by biopsy * measurable disease * able to perform activities of daily living without considerable * no previous chemotherapy with gemcitabine * no more than one prior chemotherapy regimen for metastatic breast cancer * adequate bone marrow, liver and renal function * normal heart function * give written informed consent prior to entering this study. exclusion criteria: you cannot participate in this study if any of the following apply to you: * received previous treatment with gemcitabine * history of brain metastases * serious underlying medical conditions please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.